`
`
`Graham Buckton
`
`
`
`
`BPharm, AKC, C.Dir, PhD, DSc, CChem, FRSC, FAPS, FAAPS, FRPharmS
`
`Date of Birth: 30.4.60 Status: Married, 2 children
`
`
`
`Born: Brighton, Sussex.
`
`
`
`
`
`1) Personal Details
`
`Name: Graham Buckton
`
`Nationality: British
`
`
`2) Fellowship/Membership of Professional Bodies/Associations:
`
`The Royal Pharmaceutical Society of Great Britain made a Fellow in April 1997;
`The Royal Society of Chemistry made a Fellow in 1997;
`American Association of Pharmaceutical Scientists made a Fellow in 1997;
`Academy of Pharmaceutical Sciences made a Fellow in 2009.
`Member of MENSA. (lapsed)
`
`Associations/Clubs – The Athenaeum. The Worshipful Society of Apothecaries. MCC. North
`Hants Golf Club.
`
`3) Awards/Honours
`
`2012 Freedom of the City of London.
`
`2003 Science Chairman for the British Pharmaceutical Conference.
`
`2000 First recipient of the Academy of Pharmaceutical Sciences Medal, for services to UK
`Pharmaceutical Sciences (relating to the establishment of the APS by negotiating a merger
`between the previously competing activities of “UKAPS” and the “Pharmaceutical Sciences
`Group”).
`
`1998 Stig Sunner Award, presented by the USA Calorimetry Conference “in recognition of
`research and contributions to thermodynamics and thermochemistry” to a scientist under the
`age of 40.
`
`1998 Foss Near Infra red European Users Group award for best new work in near-IR
`spectroscopy
`
`1993 British Pharmaceutical Conference Science Medal
`
`
`0001
`
`MYLAN - EXHIBIT 1003
`
`

`

`1992 Pfizer Award for "excellence in published research", granted for "imaginative use
`of thermodynamic principles in the understanding and design of drug delivery systems".
`The Pfizer Awards are not open to application, and are given on the basis of review of published
`literature by senior Pfizer scientists, and senior academic advisers
`
`4) Education
`
`Institute of Directors2012 Diploma in Company Direction
`
`Institute of Directors 2012 Certificate in Company Direction.
`
`University of London 1997 Doctor of Science for research work in pharmaceutical materials
`science.
`
`King's College (KQC), University of London, Manresa Road.
`September 1982 - August 1985 Ph.D. Title: Assessment of the wettability of powders
`1985-1987 Associate of King's College (AKC) Examined course in Philosophy (part time)
`
`Chelsea College, University of London, Manresa Road.
`September 1978 - June 1981. B.Pharm. (Hons.)
`
`Varndean Sixth Form College, Brighton, Sussex.
`September 1976 - July 1978; AO level - Human Biology; 3 A levels - Mathematics, Chemistry
`and Physics.
`
`Brighton Secondary Technical School.
`September 1971 - July 1976, June 1975 3 O levels; June 1976 8 O levels
`
`5) Present Employment
`
`Managing Director of Buckton Consulting
`
`Emeritus Professor of Pharmaceutics, UCL School of Pharmacy, University of London
`and
`
`5.1) Academic
`
`Research
`
` I
`
` have an active research group and collaborate with colleagues to supervise research at UCL
`School of Pharmacy and Nottingham University
`
`The work relates to materials science applied to pharmaceutical processing and drug delivery
`systems, notably those for inhalation and oral delivery. Further details are presented below.
`
`Examining:
`
`Chair of the MPharm exam board (2002- 2012)
`
`Past-chair of the exam boards for MSc subjects.
`
`
`0002
`
`

`

`Numerous PhD degrees (in recent years venues in clude: LSOP, Kings College London,
`Imperial College, Nottingham, Cardiff, Bradford, Brighton, Portsmouth, Manchester, Aston,
`Grenwich, Canterbury, Uppsala (Sweden), Copenhagen, Oslo).
`
`I have been / am MPharm examiner at Queens University of Belfast, Cardiff, Nottingham, Kings
`College, University of Colombo, Sri Lanka, and Robert Gordon University
`
`Previously MSc examiner Kings College London and MSc Industrial Pharmacy, University of
`Brighton.
`
`5.2 Buckton Consulting (a part of Brighton City Property Ltd)
`
`Consultancy service covering:
`
`
`1) pharmaceutical physical form, formulation development, GMP manufacturing and
`regulatory considerations.
`2) Company strategic review and management
`3) Due diligence
`4) Expert witness
`
` I
`
` act as a consultant to industrial companies in UK, mainland Europe, middle east and USA.
`This is a diverse role involving advice on materials science, formulation (inhalation and oral
`products), regulatory, and as an expert witness in patent litigation.
`
`
`
`
`
`
`
`
`0003
`
`

`

`6) Previous employment
`
`Pharmaterials Ltd
`
` I
`
` founded Pharmaterials Ltd in 2000 to transfer advanced materials characterisation techniques
`into a commercial contract service. I developed the company to cover preformulation,
`especially salt and polymorph selection, formulation development (oral and inhalation) and GMP
`clinical trial manufacture in a large purpose built facility in Reading UK. The % of my time linked
`to this activity expanded (to 70%) to keep pace with the needs of the success of a growing
`enterprise.
`
`Pharmaterials operates on a fee for service basis and has grown through profits on income.
`
`Pharmaterials won the Queen’s Award for Enterprise in 2008 for international trade.
`
`At the time of my departure 36 staff were employed.
`
`In keeping with the success of the business, the majority stake in Pharmaterials was sold to PII
`in January 2008. The remaining stake was sold in September 2012 at hich stage I exited from
`my role as Chief Executive of the company, where I acted to directly oversee the strategic and
`business planning, financial management, business development, staffing and resource
`provision.
`
`School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX
`1988 - 2015
`
`January 2001 – April 2007 Head of Department of Pharmaceutics.
`
`Management and Leadership
`
`Of the School
`
`As Head of Department much of my time was spent discussing the management of the School,
`including preparations for previous and future research assessment exercise, teaching quality
`audit, day-to-day management and strategic directions.
`
`Internal committees:
`Member of School Council. Member of the following committees of Council: Finance,
`Nominations, Governance, Fellowship and Honorary Degrees, Audit Committee.
`Other School Committee work: Academic Board, Policy and Resources Executive,
`Policy and Resources, Research Strategy Task Force,
` Academic Standards,
`Undergraduate Studies Management Group, Pharmacy Advisory, Library and
`Information Services, Joint Committee of Academic Board and Students, Higher
`Degrees, Taught Postgraduate Studies.
`
`
`Of the Department of Pharmaceutics
`
`Pharmaceutics had 13 fte academic staff, and some 70 research staff/PhDs, also 5 technicians,
`and support services (workshop and wash-up). In my time as Head all bar 1 member of
`academic staff was either appointed or promoted.
`
`
`0004
`
`

`

`I managed the staff development and infrastructure for the departmental activities, to maximise
`the productivity, whilst working within strict financial limits.
`
` I
`
` appointed senior industrialists to positions of visiting professor to develop strategy for direction
`and funding.
`
`Teaching:
`
`Instigator of MSc in Drug Delivery (developed concept and course, then transferred to staff to
`manage)
`
`Provide direction for all teaching in Pharmaceutics through regular reviews with staff, informed
`by staff views and course review reports. Allocate staff to lead the Pharmaceutics teaching in
`each semester, manage projects and dissertations, and the examination processes.
`
` I
`
` was part of the small design team that initiated the review of the BPharm, to produce a matrix
`management teaching structure (of course coordinators and heads of departments) to allow
`better subject integration. I was part of the group that assigned subjects to semesters and
`planned the curriculum, I was one of the first course coordinators. This structure was expanded
`to form the basis of the existing MPharm.
`
`Previous positions at the School of Pharmacy, University of London
`
`July 1998 Professor of Pharmaceutics;
`May 1995 Reader in Pharmaceutics;
`February 1991 Senior Lecturer in Pharmaceutics;
`September 1988 Lecturer in Pharmaceutics;
`
`Lecturer in Pharmacy (Pharmaceutics)
`Chelsea Department of Pharmacy, King's College (KQC), University of London, Manresa Road,
`London, SW3 6LX.
`October 1984 - September 1988
`Advanced Drug Delivery Research unit, Ciba-Geigy Pharmaceuticals, Horsham.
`July to December 1987 (Secondment)
`
`
`Charing Cross Hospital, Fulham Palace Road, London.
`August 1981 - July 1982. Pre-registration pharmacist
`
`Community Pharmacy Locum work (1982-1988)
`
`
`0005
`
`

`

`7) External activities
`
`Currently
`
`Member of the Chemistry, Pharmacy and Standards Subcommittee of CHM (2005-)
`
`Member of the United States Pharmacopoeia Expert Group on Physical Methods
`(20010-)
`
`Steering Committee of The Handbook of Pharmaceutical Excipients
`
`
`
`Editorial Board of Recent Patents on Drug Delivery and Formulation. Advances in
`Pharmaceutics.
`
`Previously:
`
`
`British Pharmacopoeia Commissioner (2004-2010)
`
`Member of the BP committee on pharmacy (2005-2012)
`
`
`Member of a European Pharmacopoeia Working Party (2008-2010)
`
`Member of Committee on Safety of Medicines until it was disbanded in 2005.
`
`Chairman of Chemistry, Pharmacy and Standards sub-committee of CSM and member
`of this committee previously.
`
`Editor of International Journal of Pharmaceutics (1999-2009)
`
`Editorial board member of: Pharmaceutical Research, The AAPS Journal, AAPS
`PharmSci Tech
`
`Course organiser for RPSGB residential meeting on "Tabletting Technology" (Every year
`1989 - 2004)
`
`Member of the Committee of the Pharmaceutical Sciences Group of the Royal
`Pharmaceutical Society, now the Academy of Pharmaceutical Sciences (1994 - 2001)
`
`Chairman of the RPSGB Pharmaceutical Sciences Group (1995-7).
`
`Member of the RPSGB Science Committee and also British Pharmaceutical Conference
`Committee (during period 1995-2003)
`
`Chairman for 1997 AAPS/RPSGB Arden House Conference (Europe). Faculty member
`for Arden House USA.
`
`Member of IUPAC Commission on Thermodynamics task group – Calibration of
`calorimeters.
`
`The first Chairman of the Academy of Pharmaceutical Sciences of Great Britain (1999-
`2000).
`
`
`
`
`
`
`
`0006
`
`

`

`
`Chairman for the 2005 AAPS/APS/RPSGB Arden House Conference (Europe),
`Planning committee Arden House USA. (First person to have chaired this prestigious
`meeting twice).
`
`Course organizer / Planning Committee member for numerous international conferences
`across Europe.
`
`
`8) Research
`
`The central theme of my research is to investigate the behaviour of materials of pharmaceutical
`importance in terms of their molecular and interfacial properties and to relate such behaviour to
`processing and drug delivery.
`
`Current work is diverse in application, ranging from fundamental studies on surfaces, through
`the adaptation of physical properties of powders by crystallisation and physical manipulation
`(e.g. milling), to the preparation and characterisation of dosage forms (solid oral / inhalation). A
`major part of my work centres on investigations of powder / water interactions. The implications
`of powder / water interactions are manifold, influencing many aspects, including product (solid
`and liquid dosage forms) preparation, usage (e.g. drug release), and stability (microbiological,
`chemical and physical). With such diverse applications, the scope of this research grows with
`each experiment, new avenues are constantly discovered.
`
`8.1) Grants obtained
`
`1987 Glaxo Group Research fully funded PhD student (Effect of processing and chemical
`structure on surface energetics) ca £25,000.
`1987 Ciba-Geigy Advanced Drug Delivery Research fully funded PhD student (Binding of
`opsonising proteins to drug conjugates) ca£23,000.
`1987 Glaxo Group Research £2,500 to purchase equipment.
`1987 Lilly Research Ltd. Gift of computing equipment (value £6,000).
`1988 Wellcome Foundation Ltd. £10,000 for equipment.
`1988 Wellcome Foundation Ltd. £1,000
`for work on
`polymorphs.
`1988 Wellcome Foundation Ltd. Fully funded PhD student (Crystal engineering and surface
`energetics) ca£23,000.
`1988 SERC CASE
`- Lilly Research Centre Ltd. PhD student, The stability of
`inhalation aerosols, plus ongoing gifts of equipment ca £28,000.
`1988 Upjohn Ltd. Summer studentship £1000.
`1988 Wellcome Foundation Ltd. Summer studentship £1000.
`1988 Lilly Research Centre Ltd, Two summer studentships £2000.
`1988 Wellcome Foundation Ltd., Fully funded PhD student £25,000
`1988 SERC/ CASE award with Beecham Pharmaceuticals, £25,000
`1989 Wellcome Foundation Ltd. £1,876 towards equipment.
`1989 Wellcome Trust Summer Studentship £622
`1989 Lilly Research Summer Project (£750)
`1990 British Council Travel Award to visit University of Athens (£2800).
`1990 SERC/CASE award with MSD, Computer modelling as a means of predicting
`
`powder properties. £30,000
`1991 The Wellcome Trust, £29,639 to purchase a microcalorimeter.
`1992 The Wellcome Foundation £33,000 for PhD studentship
`
`surface energetics of
`
`0007
`
`

`

`for PhD studies, with collaborative
`
`funding
`
`to study drug-surfactant
`
`inverse phase gas
`
`1992 Thermometric Ltd. - £12,000 of calorimetric equipment.
`1993
` The Wellcome Foundation Ltd.
` - £15,000
`for employment of a research
`Technician.
`1993
` School of Pharmacy studentship
`obtained from MSD (£30,000).
`1993 SERC/CASE award with MSD (£30,000.
`1993 The Wellcome Trust, Characterisation of powder surface properties, with
`application to inhaled drug delivery, £100,515
`1994 Roche Products Ltd., Surface properties of powders in relation to tabletting. ca
`£40,000 over 3 years.
`1994 EPSRC ROPA award (the first of such awards to be made), £47,940 for the
`purchase of a microcalorimeter.
`1994 The Wellcome Foundation, £750 towards maintenance of the microcalorimeter.
`1994 Pharmacia Farmitalia, £4,000 towards the cost of a project on bioadhesion.
`1994 SERC/CASE award, SB Pharmaceuticals - molecular structure, crystal packing and
`physico-chemical properties of drugs.(£40,000)
`1994 Wellcome Foundation, gift of equipment and software for instrumentation of atabletting
`machine ca £10,000..
`1995 Merck, West Point, USA, £43,000 over 3 years
`interactions.
`1995 Pfizer Central Research, £43,000 over 3 years to study powder mixing.
`1995 SB Pharmaceuticals, industrial CASE allocation, to study spray granulation.
`1996 Glaxo-Wellcome, £43,500 over 3 years to study microfluidisation technologies.
`1996 Mendell ca £21,000 for studies on microcrystalline cellulose.
`1997 Astra Charnwood £45,000 over 3 years to study surfactant systems
`1997 SB/Roche/Pfizer £190,000 over 3 years
`to develop
`chromatography
`1997 EPSCR/MSD Case project ca £45,000 over 3 years to study drying processes.
`1997 Mendell £25,000 for further studies on microcrystalline cellulose.
`1997 Mendell £7,500 for calorimetry accessories.
`1998 ICI, application of isothermal microcalorimetry £60,000
`1998 Core Technologies, post-doctoral worker on hydrogel technology, ca £65,000
`1998 Elan Pharmaceuticals, post-doctoral worker on surfactant systems, ca£65,000
`1998 Pfizer Central Research, PhD on powder mixing, £50,000
`1998 Industrial BBSRC/CASE award from SB pharmaceuticals, £50,000
`1998 RPSGB Award to Sarah Hogan for PhD studentship, ca £45,000
`1999 Novartis studies of dry powder inhaler design £69,000
`1999 EPSRC CASE with SB Pharmaceuticals- powder surface charactersiation £48,000
`2000 BBSRC committee student to study stabilisation of solid state macromolecules
`£60,000.
`2001 EPSRC/GSK - £20,550 to fund study of Dynamic vapour sorption technique
`2001 AstraZeneca - £50,000 to fund study on Modification of surfaces of microparticles for
`inhalation
`2001 GSK - £20,550 to fund investigations into predicting physical stability of amorphous
`compounds
`2001 EPSRC - £192,271 to fund study of preparation and characterisation of amorphous
`pharmaceutical blends from libraries of polymers
`2001 Schering Plough
`- £50,000 The effect of milling process on crystalline
`materials.
`2002 Pfizer Central Reseacrh £150,000
`(with Ian Wong)
`
`for Paediatric Pharmacy
`
`to
`
`fund Centre
`
`0008
`
`

`

`2003 AstraZeneca – 45,000 First studentship rolling scheme.
`2002 £4000 bench fee for visiting scientist (Dr Ohta from Japan)
`2003 Meiji Seika Daisha Ltd – £7,000 Bench fee for visiting Scientist
`2004 Pfizer Central Research £60,000 for PhD student on inhalation formulation.
`2005 EPSRC Academic Fellowship Scheme, £125,000 for Solid state DNA vaccine particles for
`inhaled drug delivery. (5 year fellowship jointly funded by School), with Prof Alpar.
`2005 BBSRC £50,000 for establishment of distance learning MSc in Drug Delivery.
`2005 Astra Zeneca ca £60,000 for PhD student on the stability of pressurized metered dose
`inhalers
`2006 Pfizer Central Research ca £80,000 for PhD student on Process Analytical Technology
`2006 Maplethorpe post doctoral grant – surface energy determination using AFM and IGC c
`£80,000.
`2012 EPSRC DTC with Uni of Nottingham, Pfizer, AZ, GSK and other £1,950,000.
`2014 EPSRC DTC with Nottingham £11,800,000
`
`8.2) Publications
`
`8.2.1) Single authored book
`
`Interfacial phenomena in drug delivery and targeting.
`
`G.Buckton, Harwood Academic Press, Amsterdam, (1995). Part of the series in Targeting and
`Drug Delivery
`
`8.2.2) Book
`
`Pharmaceutical Thermal Analysis (2nd Edition)
`J Ford, P.Timmins and G.Buckton. (2001) Taylor and Francis.
`
`
`8.2.3) Full Papers
`
`1) Assessment of the wettability and surface-energy of a pharmaceutical powder by liquid
`penetration.
`G.Buckton and J.M.Newton, (1985), J. Pharm. Pharmacol., 37, (9): 605-609.
`
`2) The significance of contact angles measured on surfaces that have undergone plastic
`deformation.
`G.Buckton and J.M.Newton, (1986), in Gorrod,J.W., Gibson,G.G., and Mitchard,M., (Eds.),
`Development of Drugs and Modern Medicine, Ellis Horwood, Southampton, pp421-424.
`
`3) Assessment of the wettability of powders by use of compressed powder discs.
`G.Buckton and J.M.Newton, (1986), Powder Technol., 46, (2-3): 201-208.
`
`4) Liquid penetration as a method of assessing the wettability and surface energy of
`pharmaceutical powders.
`G.Buckton and J.M.Newton, (1986), J. Pharm. Pharmacol., 38, (5): 329-334
`
`5) A vacuum microbalance technique for studies on the wettability of powders.
`G.Buckton, A.E.Beezer and J.M.Newton, (1986), J. Pharm. Pharmacol., 38, (10):
` 713-720.
`
`
`0009
`
`

`

`6) The potential value of dielectric response measurements in the assessment of the wettability
`of powders.
`G.Buckton, L.A.Dissado, R.M.Hill and J.M.Newton, (1987), Int. J. Pharm., 38, (1-3): 1-7.
`
`7) A microcalorimetric study of powder surface energetics.
`G.Buckton and A.E.Beezer, (1988), Int. J. Pharm., 41, (1-2): 139-145.
`
`8) In vitro dissolution of some commercially available sustained release theophylline
`preparations.
`G.Buckton, D.Ganderton and R.Shah, (1988), Int. J. Pharm., 42, (1-3): 35-39.
`
`9) Preservation of oral solid dosage forms.
`T.C.Blair, G.Buckton and S.F.Bloomfield, (1988), in Bloomfield, S.F., Leech,R., Baird,R. and
`Leak,R., (Eds.), Microbial Quality Assurance of Pharmaceuticals, Cosmetics and Toiletries,
`Ellis Horwood, Southampton, pp104-118.
`
`10) Effect of comminution technique on the surface energy of a powder.
`G.Buckton, A.Choularton, A.E.Beezer and S.M.Chatham, (1988), Int. J. Pharm. 47, (1-3): 121-
`128.
`
`11) The assessment, and pharmaceutical importance, of the solid / liquid and the solid / vapour
`interface: a review with respect to powders. Invited review.
`G. Buckton, (1988) Int. J. Pharm., 44, (1-3): 1-8.
`
`12) Structure-activity relationships for solubility and wettability of a number of substituted
`barbituric acids.
`G.Buckton and A.E.Beezer (1989) Thermochimica Acta., 138, (2): 319-326
`
`13) In vitro dissolution testing of oral controlled release preparations in the presence of artificial
`foodstuffs. I) Exploration of alternative methodology: microcalorimetry.
`L.J.Ashby, A.E.Beezer and G.Buckton, (1989), Int. J. Pharm., 51, (3): 245-251.
`
`14) In vitro dissolution testing of oral controlled release preparations in the presence of artificial
`foodstuffs. II) Probing drug / food interactions using microcalorimetry.
`G.Buckton, A.E.Beezer, S.M.Chatham and K.K.Patel, (1989), Int J Pharm., 56, (2): 151-157.
`
`15) The use of surface-energy values to predict optimum binder selection for granulations.
`L.Zajic and G.Buckton, (1990), Int. J. Pharm., 59, (2): 155-164.
`
`16) Contact-angle, adsorption and wettability - a review with respect to powders. Invited review.
`G.Buckton, (1990), Powder Technol., 61, (3): 237-249.
`
`17) Modelling drug release from hydrophobic matrices by use of thermodynamic activation
`parameters.
`M.Efentakis and G.Buckton,(1990), Int. J. Pharm., 60, (3): 229-234.
`
`18) Particle growth in aqueous suspension: the influence of surface-energy and polarity.
`S.A.Young and G.Buckton, (1990), Int. J. Pharm., 60, (3): 235-241.
`
`19) Polyoxyethylene - polyoxypropylene block copolymers: a novel phase transition in aqueous
`solution of Pluronic F87.
`
`0010
`
`

`

`N.Mitchard, A.E.Beezer, N.Rees, J.Mitchell, S.Leharne, B.Chowdhry and G.Buckton, (1990),
`J.Chem. Soc., Chem. Commun. (13): 900-901.
`
`20) The use of thermodynamic activation parameters and compensation analysis to model drug
`release from hydrophobic matrices.
`G.Buckton and M.Efentakis, (1990), Int. J. Pharm., 62, (2-3): 157-163.
`
`21) The interaction of various types of microcrystalline cellulose and starch with water.
`T.C.Blair, G.Buckton, A.E.Beezer and S.F.Bloomfield, (1990), Int. J. Pharm., 63, (3): 251-257.
`
`22) The role of compensation analysis in the study of wettability, solubility, disintegration and
`dissolution.
`G.Buckton, (1990), Int. J. Pharm., 66, (1-3): 175-182.
`
`23) Problem based learning - a valuable approach to pharmaceutical education.
`G.Buckton and I.P.Bates, (1991), Int. Pharm. J., 5: 7-13.
`
`24) Modelling drug release from matrix formulations by use of thermodynamic activation
`parameters and extrathermodynamics.
`G.Buckton, M.Efentakis and Z.Hussain, (1991), Eur. J. Pharm. Biopharm., 37, (3):154-158.
`
`25) Solution thermodynamics of 4-hydroxybenzoates in water, 95 % ethanol / water,
`1-octanol and hexane.
`A.E.Beezer, G.Buckton, S.Forster, W-B.Park and G.J.Rimmer, (1991), Thermochimica Acta,
`178: 59-65.
`
`26) Spreading coefficients: the practical application of surface energy and polarity data. Invited
`review.
`G.Buckton, (1991), Pharmakeftiki, 3: 145-149.
`
`27) The influence of surfactants on drug release from a hydrophobic matrix.
`M.Efentakis, H.Al-Hmoud, G.Buckton and Z.Rajan, (1991), Int. J. Pharm., 70, (1-2): 153-158.
`
`28) On the mechanism of kill of microbial contaminants during tablet compression.
`T.C.Blair, G.Buckton and S.F.Bloomfield, (1991), Int. J. Pharm., 72, (2): 111-115.
`
`29) The effect of surface treatment on the values of contact angles measured on a compressed
`powder surface.
`I.O.Odidi, J.M.Newton and G.Buckton, (1991), Int. J. Pharm., 72, (1): 43-49.
`
`30) The importance of chain-length on the wettability and solubility of organic homologs.
`S.Forster, G. Buckton and A.E.Beezer, (1991), Int. J. Pharm., 72, (1): 29-34.
`
`31) Sustained release (SR) theophylline preparations: A review of biopharmaceutical
`influences on in vivo and in vitro drug absorption / release data. Invited review.
`G. Buckton, (1991), J. Biopharm. Sci., 2 : 81-96.
`
`32) Pharmaceutical microcalorimetry: a selective review. Invited review.
`G.Buckton, S.Russell and A.E.Beezer, (1991), Thermochim. Acta, 193: 195-214
`
`33) The applications of microcalorimetry to the field of physical pharmacy.
`
`0011
`
`

`

`G.Buckton and A.E.Beezer, (1991), Int. J. Pharm., 72, (3): 181-191 (Invited review).
`
`34) Surface analysis of pharmaceutical powders. I) X-ray photoelectron spectroscopy (XPS)
`related to powder wettability.
`G.Buckton, R.Bulpett and N. Verma, (1991), Int. J. Pharm., 72, (2):157-162.
`
`35) The influence of surfactants on drug release from acrylic matrices.
`G.Buckton, M.Efentakis, H.Al-Hmoud and Z.Rajan, (1991), Int. J. Pharm., 74, (2-3): 169-174.
`
`36) Observations on the biopharmaceutical importance of chain-length in pharmaceutically
`related compounds.
`G.Buckton, A.E.Beezer, S.P.Denyer and S.J.Russell, (1991), Int. J. Pharm., 73, (1): 1-7.
`
`37) NMR evidence for novel phase transition in aqueous solutions of pluronic-F87 (poloxamer
`237).
`A.E.Beezer, J.C.Mitchell, N.H.Rees, J.K.Armstrong, B.Z.Chowdhry, S.Leharne and G.Buckton,
`(1991), J. Chem. Res. (9): 254-255.
`
`38) Safety aspects of non-ionic surfactant vesicles: A toxicity study related to the physico-
`chemical characteristics of non-ionic surfactants.
`H.E.J.Hofland, J.A.Bouwstra, J.C.Verhoef, G.Buckton, B.Z.Chowdhry, M.Ponec and
`H.E.Junginger, (1992), J. Pharm. Pharmacol.,44, (4): 287-294.
`
`39) The use of high sensitivity differential scanning calorimetry to characterise dilute aqueous
`dispersions of surfactants.
`G.Buckton, B.Z.Chowdhry, J.K.Armstrong, S.A.Leharne, J.A.Bouwstra and H.E.J.Hofland,
`(1992), Int. J. Pharm., 83, (1-3): 115-121.
`
`40) The extent of errors associated with contact angles obtained using liquid penetration results.
`G.E.Parsons, G.Buckton and S.M.Chatham, (1992), Int. J. Pharm., 82, (1-2): 45-150.
`
`41) The estimation and application of surface energy data for powdered systems.
`G.Buckton, (1992), Drug Dev. Ind. Pharm., 18, (11-12): 1149-1167, Invited Review.
`
`42) Drug release from gel bases: A case for enthalpy-entropy compensation.
`G.Buckton and S.Tamburic, (1992), J. Cont. Rel., 20, (1): 29-36.
`
`43) The use of surface energy and polarity determinations to predict the physical stability of
`non-polar non-aqueous suspensions.
`G.E.Parsons, G.Buckton and S.M.Chatham, (1992), Int. J. Pharm., 83, (1-3): 163-170.
`
`44) The influence of four selected processing and formulation factors on the production of
`spheres by extrusion and spheronisation.
`J.F.Pinto, G.Buckton and J.M.Newton, (1992), Int. J. Pharm., 83, (1-3): 187-196.
`
`the dissolution of promethazine hydrochloride
`45) Temperature effects on
`hydroxypropylmethylcellulose matrix tablets: the role of compensation analysis.
`G.Buckton, (1992), Eur. J. Pharm. Biopharm., 38, (5): 172-173.
`
`46) High sensitivity scanning microcalorimetry study of phase transitions in dilute solutions of
`polyoxyethylene-polyoxypropylene block copolymers.
`
`from
`
`0012
`
`

`

`A.E.Beezer, N.Mitchard, J.C.Mitchell, J.K.Armstrong, B.Z.Chowdhry, S.A.Leharne and
`G.Buckton, (1992), J. Chem. Res., (7): 236-238.
`
`47) The relationship between particle size and solubility.
`G.Buckton and A.E.Beezer, (1992), Int. J. Pharm., 82, (3): R7-10.
`
`48) The effect of surfactant charge on drug release from acrylic matrices.
`M.Efentakis, G.Buckton and H. Al-Hmoud, (1992), STP Pharma Sciences, 4: 332-336.
`
`49) Thermodynamic analysis of scanning calorimetric transitions observed for dilute aqueous
`solutions of ABA block copolymers.
`N.Mitchard, A.E.Beezer, J.C.Mitchell, J.K.Armstrong, B.Z.Chowdhry, S.Leharne and G.Buckton,
`(1992), J. Phys. Chem., 96, (23): 9507-9512.
`
`50) Assessment of the wettability of pharmaceutical powders.
`G.Buckton, (1993), J. Adhesion Sci. Technol., 7, (3): 205-219. Invited Review.
`
`51) Factors influencing the mechanism of release from sustained-release matrix pellets,
`produced by extrusion / spheronisation.
`C.Tapia, G.Buckton and J.M.Newton, (1993), Int. J. Pharm., 92, (1-3): 211-218
`
`52) Comparison of measured wetting behaviour of materials with identical surface energies,
`presented as particles and plates.
`G.E.Parsons, G.Buckton and S.M.Chatham, (1993), J. Adhesion Sci. Technol., 7, (2): 95-104.
`
`53) Isothermal stability of dilute aqueous solutions of block copolymers of polyoxyethylene-
`polyoxypropylene-polyoxyethylene. A microcalorimetric study of pluronic F 87 (poloxamer 237)
`and pluronic F88 (poloxamer P238).
`J.J.Irwin, A.E.Beezer, J.C.Mitchell, G.Buckton, B.Z.Chowdhry, D.Eagland and N.J.Crowther
`(1993), J. Phys. Chem., 97, (9): 2034-2036.
`
`54) Swelling studies on mixtures of two hydrophilic excipients.
`E.Papadimitriuo, G.Buckton, M.Efentakis and N.Choulis, (1993), STP Pharma Sciences, 3: 232-
`236.
`
`55) Probing the mechanisms of swelling of hydroxypropylmethylcellulose matrices.
`E.Papadimitriuo, G.Buckton and M.Efentakis, (1993), Int. J. Pharm., 98, (1-3): 57-62.
`
`56) Consideration of adhesion to modified container walls, by use of surface energy and polarity
`data, and Lewis acid - Lewis base interactions.
`G.Buckton and B.Chandaria, (1993) Int. J. Pharm., 94, (1-3): 223-229.
`
`57) Assessment of the wettability of pharmaceutical powders.
`G.Buckton, (1993), in Mittal,K.L. (Ed.), Contact Angle, Wettability and Adhesion, VSP,
`Netherlands, pp 437-451.
`
`58) Pharmaceutical preformulation
`G.Buckton, (1994), in W.Lund, (Ed.), The Pharmaceutical Codex: Principles and Practice of
`Pharmaceutics, 12th Edn., The Pharmaceutical Press, London, pp178-197.
`
`
`0013
`
`

`

`59) An investigation into the structure and properties of Carbopol 934 gels using dielectric
`spectroscopy and oscillatory rheometry.
`D.Q.M.Craig, A.Tamburic, G.Buckton and J.M.Newton, (1994), J. Cont. Rel., 30, (3): 213-223.
`
`60) The use of isothermal microcalorimetry in the study of changes in crystallinity induced
`during the processing of powders.
`L-E. Briggner, G.Buckton, K.Bystrom and P Darcy, (1994), Int. J. Pharm., 105, (2): 125-135.
`
`61) The extent of errors associated with contact angles. II. Factors affecting data obtained
`using a Wilhelmy plate technique for powders.
`P.L.Sheridan, G.Buckton and D.E.Storey, (1994), Int. J. Pharm., 109, (2): 155-171.
`
`62) The interaction of albumin and drugs with 2 hemofiltration membranes.
`C.A.Oborne, G.Buckton and N.Barber, (1994), J. Clin. Pharm. Therapeutics., 19, (2): 119-126.
`
`63) The use of high sensitivity differential scanning calorimetry to characterise dilute aqueous
`dispersions of surfactants. 2. Further studies on polyoxyethylene alkyl ethers.
`G.Buckton, J.K.Armstrong, B.Z.Chowdhry, S.Leharne and A.E.Beezer, (1994), Int. J. Pharm.,
`110, (2): 179-187.
`
`64) The controlled crystallization of a model powder: I) The effects of altering the stirring rate
`and the supersaturation profile, and the incorporation of a surfactant (Poloxamer 188).
`A.J.Mackellar, G.Buckton, J.M.Newton, B.Z.Chowdhry and C.A.Orr., (1994) Int. J. Pharm., 112,
`(1): 65-78.
`
`65) The controlled crystallisation of a model powder: II) Investigation into the mechanism of
`action of poloxamers in changing crystal properties.
`A.J.Mackellar, G.Buckton, J.M.Newton and C.A.Orr., (1994), Int. J. Pharm., 112, (1): 79-85.
`
`66) Wilhelmy plate contact angle data on powder compacts: Fractal geometry considerations of
`plate perimeter.
`A.Chawla, G.Buckton, K.M.G.Taylor, J.M.Newton and M.C.R.Johnson, (1994),Eur. J. Pharm.
`Sci., 2, (3): 253-258.
`
`67) Characterisation of powder surfaces: Understanding sources of variability in products.
`G.Buckton, (1994), In Karsa,D.R. and Stephenson,R.A., (Eds.), Excipients and Delivery
`Systems for Pharmaceutical Formulations, Royal Society of Chemistry, pp59-74.
`
`68) Application of isothermal microcalorimetry in the pharmaceutical sciences.
`G.Buckton, (1995), (invited review) Thermochimica Acta, 248: 117-129.
`
`/ poly(oxypropylene)
`in poly(oxyethylene)
`transition
`influence of a phase
`69) The
`poly(oxyethylene) surfactants on adsorption behaviour from dilute aqueous solution.
`D.Carthew, G.Buckton, G.E.Parsons and S.Poole, (1995), Pharm. Sci., 1: 3-5.
`
`70) Preservation of oral solid dosage forms.
`T.C.Flatau, S.F.Bloomfield and G.Buckton (1996), in R.M.Baird and S.F.Bloomfield, (Eds.),
`Microbial Quality Assurance of Pharmaceuticals, Cosmetics and Toiletries, 2nd Edn., Ellis
`Horwood, Southampton, pp113-132.
`
`
`/
`
`0014
`
`

`

`71) The extent of errors associated with contact angles. III. The influence of surface roughness
`effects on angles measured using a Wilhelmy plate technique for powders.
`G.Buckton, P.Darcy and D.McCarthy, (1995), Colloids and Surfaces A: Physicochemical and
`Engineering Aspects, 95, (1): 27-35.
`
`72) The use of isothermal